Pharmacy Examining Board

​​COVID-19: HEALTH CARE PROVIDERS:​​​

The Department of Safety and Professional Services has been working closely with the Pharmacy Examining Board, other health professions governing boards and councils, and Governor Evers​' administration to position our health care workforce to best respond to the COVID-19 public health emergency. For information on the state COVID-19 response, including orders and memos, please visit our COVID Information page​.​


The Pharmacy Examining Board is created under Wis. Stat. § 15.405(9), and has authority as outlined in Wis. Stat. ch. 450.

Members

The members of the Pharmacy Examining Board are appointed by the Governor and confirmed by the Legislature to serve 4-year terms. The Board consists of 5 licensed pharmacist members and 2 public members. 

MemberOfficerMember TypeTerm Expiration
​Trapskin, Philip J.​Chairperson​Pharmacist Member​7/1/2021
​Winters, Cathy J.
​Vice Chairperson
​Pharmacist Member
​7/1/2021
​Weitekamp, John G.
​Secretary
​Pharmacist Member
​7/1/2022
O'Hagan, Tiffany M.​

​Pharmacist Member
​7/1/2024
Peterangelo, Anthony D.

Pharmacist Member7/1/2023
​Walsh, Michael
​Public Member​7/1/2024
​Weiss, Shana
​​
​Public Member
​7/1/2023

*Board members whose terms have expired may continue to serve until their successor is confirmed by the Senate.


Important Information


U.S. Food and Drug Administration's lists of all currently approved interchangeable biological products.


​The following Patient Consultation Sign required by changes to Phar 7.08(7), and Delivery Insert of a board-approved copy of information as required by changes to Phar 7.08(8), have been approved by the Board for implementation in concert with revisions to Phar 7 which become effective January 1, 2021.

Patient Consultation Sign
Delivery Insert​ 




Announcements


On June 4, 2020, the Pharmacy Examining Board adopted revisions to Phar 7, relating to the practice of pharmacy. Changes to Phar 7 will become effective on January 1, 2021.

Phar 7: Practice of Pharmacy

Adoption Order (Outlines changes to rules adopted on June 4, 2020)

Please be advised that updates to the rule text in its official and final form will become available on the Legislative Reference Bureau site after the effect date of the adopted rule at this link: https://docs.legis.wisconsin.gov/code/admin_code/phar


The 2017 Quarter 4 ePDMP Report is now available.

2017 Quarter 4 e PDMP Report


Effective November 1, 2017, Phar 6 Has Been Updated Per 2017 Wisconsin Act 18

Phar 6 - Pharmacy Licenses and Equipment

2017 Wisconsin Act 18


Effective November 1, 2017, Phar 14 Has Been Updated

Phar 14 - Home Medical Oxygen Providers


Effective September 1, 2017, Phar 7.10 Has Been Updated

Phar 7.10 - Administration of drug products and devices other than vaccines


​On October 1, 2016 the following Pharmacy Chapters were updated:


Orders

Phar 1, 8 Relating to Definitions and Controlled Substances

Phar 1, 2 and 4 Relating to Application and Examination

Phar 5 Relating to Renewal and Reinstatement

Phar 8 Relating to Identification Card Required for Certain Controlled Substances



2015 Act 313 went into effect on April 1, 2016.  This Act no longer authorizes the Pharmacy Board to grant variances unless a disaster or emergency exists, but to instead institute pilot projects.  The Board is currently engaged in the transitioning of current non-emergency variances into pilot projects. Please see the link for more detailed information as to the Statutory requirements.

http://docs.legis.wisconsin.gov/statutes/statutes/450/02/3r


CSB 4.04(2)(p) goes into effect on April 9, 2017.  This requires that the name recorded under s. 450.11(1b)(bm), Stats. be submitted to the Prescription Drug Monitoring Program.


​2015 Act 291 relating to prescription fills and refills went into effect on April 1, 2016. 


Please review the following update:

NTSB Information on Risk of Pilot Impairment


As of September 1, 2014, Phar 8.05(4), 8.07(2) and 8.09 were amended to allow electronic prescriptions for schedule II controlled substances.


On August 28, 2014 the DEA published its final rule in the Federal Register placing Suvorexant into Schedule IV of the Federal Controlled Substances Act. The scheduling action was effective September 29, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to treat Suvorexant as a Schedule IV effective November 1, 2014.


On August 22, 2014 the DEA published its final rule in the Federal Register rescheduling hydrocodone combination products from Schedule III to Schedule II of the Federal Controlled Substances Act. The scheduling action was effective October 6, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly reschedule hydrocodone combination products from Schedule III to Schedule II effective November 1, 2014.


On July 2, 2014, the DEA published its final rule in the Federal Register placing tramadol into schedule IV of the federal Controlled Substances Act effective August 18, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly treat tramadol as a schedule IV controlled substance​​​​​​​​ effective September 1, 2014.


As of November 1, 2013, Phar 7.01(1)(e), Wis. Admin. Code, relating to delivery, became effective.



Last updated: 11/4/2020​